Document | Document type | Purpose | Topic | Studies reviewed related to naloxone | Year last study reviewed | Total RCTs |
---|---|---|---|---|---|---|
Bagley_2019 [45] | Scoping review | To identify US-based post-overdose intervention models described in peer-reviewed literature and implemented in public health and community settings | Effectiveness of naloxone and take-home naloxone (THN) for opioid overdose reversal | 31 | 2018 | – |
Mauri_2020 [46] | Scoping review | To synthesize the available evidence on the effectiveness of prevalent state opioid policies on improving outcomes related to opioid prescribing and dispensing, patient behavior, and patient health | Provision, feasibility and acceptability of naloxone distribution | 2 | 2018 | 2 |
Muzyk_2019 [47] | Scoping review | To identify, evaluate, and summarize published literature describing pharmacists’ attitudes toward naloxone and medications for opioid use disorder | Provision, feasibility and acceptability of naloxone distribution Naloxone training and education | 5 | 2017 | – |
Nielsen_2016 [48] | Scoping review | To understand what is currently known about community pharmacy supply of naloxone, with a particular focus on understanding current practice and supply models, and barriers that may need to be addressed in order to embed and optimize the expansion of naloxone supply through this community route. | Provision, feasibility and acceptability of naloxone distribution | 16 | 2016 | – |
Ashton_2006 [49] | Short cut/rapid review | To establish whether intranasal naloxone is effective in suspected opiate overdose. | Naloxone dosing or routes of administration | 8 | 2005 | 3 |
Barrie_2006 [50] | Short cut/rapid review | To establish whether naloxone may have an ‘awakening effect’ in patients who have not taken opiates, thereby clouding its use as a diagnostic manoeuvre. | Naloxone safety (harms or adverse events related to naloxone administration) | 3 | 1999 | 1 |
Barrie_2008 [51] | Short cut/rapid review | To establish whether the training of intravenous drug users in the use of naloxone and the prescription of that drug to those users reduces mortality from opiate overdose. | Effectiveness of naloxone and take-home naloxone (THN) for opioid overdose reversal | 3 | 2006 | – |
Brooker_2019 [52] | Short cut/rapid review | To explore the experience in administering naloxone in a home or community setting by community and lay users, community service staff, police and other non-healthcare professionals, as well as allied health professional. | Provision, feasibility and acceptability of naloxone distribution | 11 | 2019 | – |
Clarke_2002 [53] | Short cut/rapid review | To establish whether patients with no recurrence of symptoms one hour after receiving naloxone for an opioid overdose can safely be discharged. | Overdose response after naloxone administration | 5 | 2000 | – |
Ishiyama_2013 [54] | Short cut/rapid review | To establish whether nebulised naloxone is a safe and effective alternative to intravenous naloxone in reversing opioid toxicity. | Naloxone dosing or routes of administration | 2 | 2013 | – |
Kerr_2008 [55] | Short cut/rapid review | To review the effectiveness, safety and utility of intranasal naloxone for the treatment of heroin overdose. | Naloxone dosing or routes of administration | 8 | 2005 | 2 |
Marshall_2018 [56] | Short cut/rapid review | To establish psychological impacts of being a peer-helper in a take home naloxone program | Provision, feasibility and acceptability of naloxone distribution | 27 | 2015 | 4 |
Kampman_2015 [57] | Practice guidelines | To provide information on evidence-based treatment of opioid use disorder | Recommendations for policy and practice and gaps in knowledge | Unknown | No date | – |
Strike_2015 [58] | Practice guidelines | To evaluate the effectiveness of harm reduction programs that deliver prevention services to people who use drugs and are at risk for human immunodeficiency virus (HIV), hepatitis C (HCV), hepatitis B (HBV), and other harms. | Recommendations for policy and practice and gaps in knowledge | 22 | 2013 | – |
WHO_2014 [59] | Practice guidelines | To provide evidence-based recommendations on the availability of naloxone for people likely to witness an opioid overdose along with advice on the resuscitation and post-resuscitation care of opioid overdose in the community. | Recommendations for policy and practice and gaps in knowledge | 3 | 2009 | 3 |
Williams_2019 [60] | Clinical practice guidelines | To develop and disseminate an evidence-based guideline and model protocol for administration of naloxone by EMS practitioners to persons with suspected opioid overdose. | Recommendations for policy and practice and gaps in knowledge | 13 | 2016 | 3 |
CADTH_2007 [61] | Report | 1) To evaluate the clinical benefit and harm of pre-hospital use of naloxone in adult patients with opiate overdose, 2) to evaluate the clinical evidence of the different routes of administering naloxone in adult patients with opiate overdose (in a pre-hospital setting), and 3) to evaluate existing guidelines for pre-hospital administration of naloxone to adult patients with opiate overdose. | Effectiveness of naloxone and take-home naloxone (THN) for opioid overdose reversal Naloxone dosing or routes of administration | 10 | 2007 | 2 |
CADTH_2017 [62] | Report | To provide evidence on the comparative clinical effectiveness and cost effectiveness of the various formulations and delivery mechanisms of naloxone for the treatment of opioid poisoning. | Naloxone dosing or routes of administration | 3 | 2015 | 2 |
CADTH_2014 [63] | Report | To determine the comparative clinical effectiveness of intranasal (IN) versus intravenous (IV) naloxone for treatment of suspected or apparent opioid overdose in the pre-hospital setting. | Naloxone dosing or routes of administration | 2 | 2010 | – |
CADTH_2019 [64] | Report | To investigate 1) the clinical effectiveness of naloxone administered in a community or home setting and 2) The cost-effectiveness of naloxone administered in a home or community setting. | Effectiveness of naloxone and take-home naloxone (THN) for opioid overdose reversal Cost-effectiveness | 6 | 2018 | 1 |
Lobmaier_2020 [65] | Report | To review interventions for non-fatal overdoses in order to make recommendations from the literature on a standardized patient pathway, especially as it relates to post-opioid overdose interventions. | Overdose response after naloxone administration | 5 | 2019 | – |
PHO_2016 [66] | Report | To determine the effectiveness of rescue breathing only, conventional CPR, or neither by adult laypersons on survival in suspected opioid-associated resuscitation emergencies among adults in the community, compared to compression-only CPR used with or without naloxone. | Overdose response after naloxone administration | 17 | 2016 | – |
Horton_2017 [67] | Mapping review | To map research into take home naloxone for people released from correctional settings in order to identify further research needs. | Provision, feasibility and acceptability of naloxone distribution | 19 | 2016 | 3 |
Mueller_2015 [68] | Review | To classify existing publications on overdose education and naloxone distribution (OEND) programs and naloxone in community-based settings. | Provision, feasibility and acceptability of naloxone distribution Naloxone dosing or routes of administration Cost-effectiveness | 41 | No date | 2 |
McDonald_2018 [69] | Review | To examine published international patent applications of non-injectable naloxone formulations and contributory pharmacokinetic (PK) data. Three aims: 1) to trace the concept and product development by route of administration; 2) to describe the non-injectable naloxone formulations for which human in vivo data are available; and 3) to compare human PK data reported in the patent applications. | Naloxone dosing or routes of administration | 8 | 2015 | – |
Weaver_2018 [70] | Review | To investigate the various routes of naloxone administration for opioid reversal in the prehospital setting | Naloxone dosing or routes of administration | 8 | 2015 | 2 |
Willman_2016 [71] | Review | To search the medical literature related to the following questions: [25] What are the medical risks to a heroin user who refuses ambulance transport after naloxone? [1] If the heroin user is treated in the emergency department with naloxone, how long must they be observed prior to discharge? [2] How effective in heroin users is naloxone administered by first responders and bystanders? Are there risks associated with naloxone distribution programs? | Overdose response after naloxone administration | 29 | 2016 | – |